- Home
- ESPR vs CRDF Comparison
ESPR vs CRDF Comparison
Compare ESPR & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- CRDF
- Stock Information
- Founded
- ESPR 2008
- CRDF 1999
- Country
- ESPR United States
- CRDF United States
- Employees
- ESPR N/A
- CRDF N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ESPR Health Care
- CRDF Health Care
- Exchange
- ESPR Nasdaq
- CRDF Nasdaq
- Market Cap
- ESPR 208.1M
- CRDF 169.6M
- IPO Year
- ESPR 2013
- CRDF N/A
- Fundamental
- Price
- ESPR $1.07
- CRDF $3.18
- Analyst Decision
- ESPR Buy
- CRDF Strong Buy
- Analyst Count
- ESPR 7
- CRDF 4
- Target Price
- ESPR $5.93
- CRDF $12.25
- AVG Volume (30 Days)
- ESPR 4.1M
- CRDF 1.2M
- Earning Date
- ESPR 08-11-2025
- CRDF 08-07-2025
- Dividend Yield
- ESPR N/A
- CRDF N/A
- EPS Growth
- ESPR N/A
- CRDF N/A
- EPS
- ESPR N/A
- CRDF N/A
- Revenue
- ESPR $259,574,000.00
- CRDF $587,000.00
- Revenue This Year
- ESPR $4.07
- CRDF N/A
- Revenue Next Year
- ESPR N/A
- CRDF N/A
- P/E Ratio
- ESPR N/A
- CRDF N/A
- Revenue Growth
- ESPR 12.99
- CRDF N/A
- 52 Week Low
- ESPR $0.69
- CRDF $2.01
- 52 Week High
- ESPR $3.94
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- ESPR 51.40
- CRDF 41.74
- Support Level
- ESPR $1.13
- CRDF $2.98
- Resistance Level
- ESPR $1.22
- CRDF $3.99
- Average True Range (ATR)
- ESPR 0.08
- CRDF 0.29
- MACD
- ESPR 0.00
- CRDF -0.08
- Stochastic Oscillator
- ESPR 52.38
- CRDF 5.34
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.